The partnership combines GE Healthcare’s renowned expertise in the design and development of innovative bio-manufacturing technologies and Avalon’s scientific and clinical expertise for the cellular medicine industry
FREEHOLD, N.J., July 22, 2019 (GLOBE NEWSWIRE) — Avalon GloboCare Corp. (AVCO), a leading clinical-stage global developer of cell-based technologies and therapeutics, today announced that they have established a strategic partnership with GE Healthcare. The partnership will accelerate Avalon’s standardization, automation and bio-production for clinical-grade Chimeric Antigen Receptor (CAR)-T cells and other immune-effector cells for cellular immunotherapy, as well as exosomes/extracellular vesicles (EV) based regenerative therapeutics. The combination of expertise sets the stage for Avalon to be the leader in cellular medicines with the ability to execute on the complete development lifecycle from innovation through bio-production to the delivery and management of treatment at hospitals for patients. This infrastructure and depth of capabilities ensures the successful execution of the company’s ongoing clinical trials.
Under this partnership, both Avalon and GE Healthcare will strategically establish automated and standardized GMP cell production capabilities. Avalon will be given access to GE Healthcare’s cell processing expertise and products in the form of FlexFactory Cell Therapy platform, FastTrak process development and training services, as well as extensive SOP and validation protocol library. Additionally, user training will be conducted both at GE Healthcare and on-site at Avalon’s Nanjing Epicon GMP facility with access to GE Healthcare’s expert bio-manufacturing resources. In conjunction with Avalon’s extensive clinical network in China, this strategic partnership will empower Avalon to improve manufacturing throughput and efficiency, alleviate cost burden, and minimize variability in the automated and standardized bio-production process of clinical-grade cellular products (such as CAR-T, CAR-NK, and stem cell-derived exosomes/EV), therefore, accelerating the development of Avalon’s clinical and commercialization programs in cellular medicines.
“We are pleased to establish this strategic partnership with GE Healthcare. This is a crucial and exciting time in the evolution of cellular medicines and our combined skills will drive Avalon to move innovation forward and ultimately deliver the best therapeutic solutions for patients. This partnership enables Avalon to more fully leverage and integrate our core technology platforms and accelerate our clinical programs in cellular immunotherapy and stem cell-derived exosome-based regenerative therapeutics. Empowered by GE’s leading automation and standardized cell processing/bio-production capabilities, we look forward to further upgrading our infrastructure, services and products, as well as expanding our leadership role in cellular medicines,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare.
“Cellular medicines as a bio-industry sector has been growing and evolving at a rapid pace during recent years with vast potential to change the way various diseases are managed. GE Healthcare continues
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (AVCO) is a clinical-stage, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative exosome technologies and cellular therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth, development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics (”liquid biopsy”), cellular immunotherapy (including CAR-T/CAR-NK), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com
About GE Healthcare
GE Healthcare helps therapy innovators, researchers and healthcare providers accelerate how precision diagnostics and therapies are invented, made and used. The products enable biological analysis, research, development and the manufacture of advanced therapies and vaccines. From medical imaging, software and IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies, cellular medicines, and performance improvement solutions, GE Healthcare aims to improve outcomes for healthcare providers and for therapy innovators around the world to achieve increased capacity, improved productivity and better patient outcomes. For more information about GE Healthcare, please visit www.gehealthcare.com
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.
Disclaimer:
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth and INS were compensated a total of fifty thousand dollars cash for the creation and dissemination of this content between July 18, 2019 and August 18, 2019. Avalon GloboCare has retained INS Media & Spotlight Growth to provide investor relations services.
This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com//disclosures/
